ES458691A1 - Procedimiento para preparar polipeptidos. - Google Patents

Procedimiento para preparar polipeptidos.

Info

Publication number
ES458691A1
ES458691A1 ES458691A ES458691A ES458691A1 ES 458691 A1 ES458691 A1 ES 458691A1 ES 458691 A ES458691 A ES 458691A ES 458691 A ES458691 A ES 458691A ES 458691 A1 ES458691 A1 ES 458691A1
Authority
ES
Spain
Prior art keywords
substitution
luliberine
luteinizing hormone
azaglycine
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES458691A
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of ES458691A1 publication Critical patent/ES458691A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)
ES458691A 1976-05-11 1977-05-11 Procedimiento para preparar polipeptidos. Expired ES458691A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB19327/76A GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide

Publications (1)

Publication Number Publication Date
ES458691A1 true ES458691A1 (es) 1978-08-16

Family

ID=10127509

Family Applications (1)

Application Number Title Priority Date Filing Date
ES458691A Expired ES458691A1 (es) 1976-05-11 1977-05-11 Procedimiento para preparar polipeptidos.

Country Status (27)

Country Link
US (1) US4100274A (en])
JP (1) JPS52136172A (en])
AT (2) AT379400B (en])
AU (1) AU508025B2 (en])
BE (1) BE854467A (en])
BG (1) BG60740B2 (en])
CA (1) CA1101844A (en])
CH (2) CH627151A5 (en])
CS (1) CS199673B2 (en])
DD (1) DD136738A5 (en])
DE (1) DE2720245C2 (en])
DK (1) DK149596C (en])
ES (1) ES458691A1 (en])
FI (1) FI64139C (en])
FR (1) FR2351092A1 (en])
GB (1) GB1524747A (en])
HU (1) HU179990B (en])
IE (1) IE44426B1 (en])
IL (1) IL52014A (en])
NL (2) NL191793C (en])
NO (2) NO147304C (en])
NZ (1) NZ183931A (en])
PL (2) PL108860B1 (en])
SE (2) SE437837B (en])
SU (1) SU910116A3 (en])
YU (1) YU40672B (en])
ZA (1) ZA772433B (en])

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
JPH0284272U (en]) * 1988-12-20 1990-06-29
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
IL93693A (en) * 1989-03-10 2000-01-31 Endorech Inc Pharmaceutical compositions for the treatment of estrogen sensitive diseases
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
HUT60280A (en) * 1989-07-07 1992-08-28 Endorecherche Inc Process for producing androgen derivatives inhibiting sexual steroidal activity, as well as pharmaceutical compositions comprising same
ES2189784T3 (es) * 1989-07-07 2003-07-16 Endorech Inc Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
GB9112859D0 (en) * 1991-06-14 1991-07-31 Ici Plc Peptide process
PL175591B1 (pl) * 1992-05-21 1999-01-29 Endorecherche Inc Środek farmaceutyczny do hamowania 5alfa-reduktazy testosteronowej
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
WO1999007874A1 (fr) * 1996-06-13 1999-02-18 Itoham Foods Inc. Procede de production de derives de lh-rh
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
ES2154590B1 (es) 1999-05-20 2001-11-01 Lipotec Sa Procedimiento de sintesis de peptidos en fase solida
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
CA2860306C (en) 2001-02-19 2018-04-17 Novartis Ag Treatment of solid tumors with rapamycin derivatives
DK1392313T3 (da) 2001-05-16 2007-06-25 Novartis Ag Kombination omfattende N-{5-[4-(4-methyl-piperazino-methyl)-benzoyl-amido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidin-amin og et biphosphonat
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
EP1444988A4 (en) 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
JP5227492B2 (ja) 2002-05-16 2013-07-03 ノバルティス アーゲー 癌におけるｅｄｇレセプター結合剤の使用
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CA2810477C (en) * 2002-12-13 2013-09-17 Durect Corporation Oral drug delivery system
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
CA2560162C (en) 2004-04-07 2013-05-21 Novartis Ag Inhibitors of iap
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AR049938A1 (es) * 2004-06-25 2006-09-13 Takeda Pharmaceutical Derivados de metastina y utilizacion de los mismos
SI2767292T1 (sl) * 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
US20090036435A1 (en) 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
RU2436575C2 (ru) * 2005-01-21 2011-12-20 Астекс Терапьютикс Лимитед Соединения для использования в фармацевтике
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
ATE452145T1 (de) 2005-05-03 2010-01-15 Novetide Ltd Verfahren zur herstellung von peptidderivaten
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20080255149A1 (en) 2005-09-27 2008-10-16 Novartis Ag Carboxyamine Compounds and Methods of Use Thereof
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
EP2026800A1 (en) 2006-05-09 2009-02-25 Novartis AG Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
RU2009115954A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
EP2268612B1 (en) 2008-03-24 2014-08-20 Novartis AG Arylsulfonamide-based matrix metalloprotease inhibitors
JP5330498B2 (ja) 2008-03-26 2013-10-30 ノバルティス アーゲー 脱アセチル化酵素ｂのヒドロキサメートを基にした阻害剤
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
KR20160124264A (ko) * 2008-11-28 2016-10-26 노파르티스 아게 Ｈｓｐ90 억제제 및 ｍｔｏｒ 억제제를 포함하는 제약 조합물
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
ES2475945T3 (es) 2009-06-26 2014-07-11 Novartis Ag Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
US8497368B2 (en) 2009-08-12 2013-07-30 Novartis Ag Heterocyclic hydrazone compounds
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
CN102574785A (zh) 2009-08-26 2012-07-11 诺瓦提斯公司 四取代的杂芳基化合物和它们作为mdm2和/或mdm4调节剂的用途
WO2011029915A1 (en) 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
PE20121471A1 (es) 2009-11-04 2012-11-01 Novartis Ag Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
EA201200823A1 (ru) 2009-12-08 2013-02-28 Новартис Аг Гетероциклические производные сульфонамидов
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
MX382074B (es) 2010-06-16 2025-03-12 Endorecherche Inc Procedimientos de tratamiento o prevención de enfermedades relacionadas con estrógenos.
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
JP2013528635A (ja) 2010-06-17 2013-07-11 ノバルティス アーゲー ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
US20130338152A1 (en) 2011-03-08 2013-12-19 Irm Llc Fluorophenyl bicyclic heteroaryl compounds
BR112013027395A2 (pt) 2011-04-28 2017-01-17 Novartis Ag inibidores de 17alfa-hidroxilase/c17,20-liase
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
KR20140034898A (ko) 2011-06-09 2014-03-20 노파르티스 아게 헤테로시클릭 술폰아미드 유도체
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
SG195067A1 (en) 2011-06-27 2013-12-30 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
MY170922A (en) 2011-12-22 2019-09-18 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
KR20140107573A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
EA201491265A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
EP2794589A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
CA2859869A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
EA201491260A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
CN104582732A (zh) 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
KR20150042256A (ko) 2012-08-13 2015-04-20 노파르티스 아게 비장 티로신 키나제 (syk)의 억제제로서의 비시클릭 헤테로아릴 시클로알킬디아민 유도체
PT3023415T (pt) 2012-10-02 2018-02-27 Gilead Sciences Inc Inibidores de desmetilases de histonas
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
MD20150085A2 (ro) 2013-02-27 2016-02-29 Epitherapeutics Aps Inhibitori ai histon-demetilazelor
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
KR20160058889A (ko) 2013-09-22 2016-05-25 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
RU2016133285A (ru) 2014-01-15 2018-02-20 Новартис Аг Фармацевтические комбинации
EP3122730B1 (en) 2014-03-28 2020-03-25 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
TW201625535A (en) 2014-03-31 2016-07-16 Epitherapeutics Aps Inhibitors of histone demethylases
AU2015241198A1 (en) 2014-04-03 2016-11-17 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CA3155594A1 (en) * 2019-09-26 2021-04-01 S.I.S. Shulov Innovative Science Ltd. Topical anti-aging compositions comprising a tetrapeptide
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
EP4090353A4 (en) 2020-01-13 2023-08-09 Durect Corporation DELAYED-RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED PROCEDURES

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US3901872A (en) * 1974-03-13 1975-08-26 American Home Prod P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates
JPS50142563A (en]) * 1974-04-26 1975-11-17
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US3971737A (en) * 1975-03-24 1976-07-27 American Home Products Corporation [2-Methyl-Ala6 ]LRH
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US3992530A (en) * 1975-12-08 1976-11-16 American Home Products Corporation [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides

Also Published As

Publication number Publication date
DK149596C (da) 1987-01-05
CS199673B2 (en) 1980-07-31
AT379400B (de) 1985-12-27
ATA335877A (de) 1985-05-15
SU910116A3 (ru) 1982-02-28
GB1524747A (en) 1978-09-13
JPS6113480B2 (en]) 1986-04-14
NL970002I2 (nl) 1997-05-01
JPS52136172A (en) 1977-11-14
SE7705432L (sv) 1977-11-12
DD136738A5 (de) 1979-07-25
NO822984L (no) 1977-11-14
SE437993B (sv) 1985-03-25
CH627151A5 (en]) 1981-12-31
PL104362B1 (pl) 1979-08-31
BE854467A (fr) 1977-11-10
FR2351092B1 (en]) 1980-02-22
SE8007763L (sv) 1980-11-05
PL108860B1 (en) 1980-05-31
IE44426L (en) 1977-11-11
DE2720245C2 (de) 1986-09-25
IL52014A (en) 1979-11-30
FI771480A7 (en]) 1977-11-12
BG60740B2 (bg) 1996-01-31
IL52014A0 (en) 1977-07-31
FR2351092A1 (fr) 1977-12-09
NO147304C (no) 1983-03-16
NO771644L (no) 1977-11-14
CA1101844A (en) 1981-05-26
YU40672B (en) 1986-04-30
AU508025B2 (en) 1980-03-06
AU2468177A (en) 1978-11-02
PL197889A1 (pl) 1978-02-13
SE437837B (sv) 1985-03-18
ZA772433B (en) 1978-03-29
NO149586B (no) 1984-02-06
AT365562B (de) 1982-01-25
ATA217979A (de) 1981-06-15
US4100274A (en) 1978-07-11
NL191793B (nl) 1996-04-01
NL191793C (nl) 1996-08-02
YU117277A (en) 1983-02-28
FI64139B (fi) 1983-06-30
NZ183931A (en) 1979-03-16
NO149586C (no) 1984-05-16
DK149596B (da) 1986-08-04
HU179990B (en) 1983-01-28
IE44426B1 (en) 1981-11-18
DE2720245A1 (de) 1977-11-24
NO147304B (no) 1982-12-06
CH629475A5 (de) 1982-04-30
FI64139C (fi) 1983-10-10
NL970002I1 (nl) 1997-03-03
NL7705130A (nl) 1977-11-15
DK207977A (da) 1977-11-12

Similar Documents

Publication Publication Date Title
ES458691A1 (es) Procedimiento para preparar polipeptidos.
ES2154627T3 (es) Estabilizacion de somatotropinas mediante la modificacion de restos de cisteina utilizando mutagenesis de localizacion dirigida o derivatizacion quimica.
ATE304020T1 (de) Parathyroidhormon-verwandthe peptidanaloge
DE69016655D1 (de) Biologisch aktive polypeptide, die auf transformierten wachstumsfaktor-beta-sequenzen basieren.
ZA202306729B (en) Novel glp-1 analogues
DK141022B (da) Fremgangsmåde til fremstilling af en antibiotisk blanding eller de enkelte komponenter betegnet teichomycin A1, teichomycin A2, teichomycin A3, antibiotisk 8327 faktor B og antibiotisk 8327 faktor C.
DK0736039T3 (da) Forbindelser med væksthormon-frigivende egenskaber
UY23804A1 (es) Procedimiento de preparacion de medicamentos en forma de comprimidos con liberacion retardada de sustancia activa.
NO911752L (no) Stabilisering av somatotropiner og andre proteiner ved modifisering av cysteinrester.
ES8405363A1 (es) Procedimiento para la obtencion de un octapeptido ciclico.
GB1329860A (en) Process for the manufacture of peptides containing cystine
ES2121804T3 (es) Nuevo interferon beta humano recombinante, procedimiento para su fabricacion y preparaciones farmaceuticas que lo contienen.
IT1212508B (it) Analoghi retro - invertiti dei penta - ed esapeptidi c - terminali della sostanza p. utili come vasodilatatori
ES2006725A4 (es) Mejoras en, o relacionadas con hormonas.
ES2149177T3 (es) Composiciones para el tratamiento del sindrome de fatiga cronica.
NL7903871A (nl) Werkwijze ter bereiding van een prostacycline bevattend farmaceutisch preparaat, alsmede als zodanig verkregen preparaten.
DK239781A (da) Peptider der er antagonister til det luteiniserende hormon frigoerende hornon (lh-rh).
EP0352816A3 (en) Il-1alpha derivates and medicament for treating thrombocytopenia
ES8606403A1 (es) Un procedimiento de preparar peptidos.
GB849175A (en) White coating composition
RU95106486A (ru) Аналоги амилина, способы лечения сахарного диабета типа i и ii и гипергликемии, способ регулирования принятия пищи
ES8501378A1 (es) Procedimiento de preparar derivados de n-cicloalcoilmetil-2 oxo-3 diaril 5-6 as triacina
GB615813A (en) Improvements relating to apparatus for use with molten glass
HU911358D0 (en) Grf analogues
ES258133A1 (es) Procedimiento para la obtenciën de nuevos polipepturos